STELARA 130 mg concentrate for solution for infusion clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants with Moderately to Severely Active Crohn’s Disease
This study is looking at a medicine called Stelara for children and teenagers with Crohn's disease. It wants to see if Stelara helps them feel better and stay well. Participants will first receive the medicine through a drip, and then by an injection under the skin.
For: Moderately to Severely Active Crohn's DiseaseHungary · Germany · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Evaluating the efficacy and safety of hyperbaric oxygen therapy as an adjuvant treatment compared to biologic therapy alone in moderate to severe ulcerative colitis in adults
This study is looking at a new way to treat severe ulcerative colitis. It tests if adding oxygen therapy to existing biologic medicines works better than biologics alone to reduce symptoms like diarrhoea and blood in your poo, and improve gut healing.
For: Ulcerative colitisPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
This study is looking at a medicine called ustekinumab (Stelara) for children and teenagers with a gut condition called ulcerative colitis. It hopes to see if it's safe and effective in helping them feel better and stay well, compared to a dummy medicine.
For: Moderately to Severely Active Ulcerative ColitisGermany · Hungary · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment
This study is looking into a new medication (BI 706321) for Crohn's disease. It aims to see if it's safe and effective when taken alongside an existing treatment called Stelara, and how it works in the body.
For: Crohn`s Disease (CD)Italy · Spain · Czechia